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Abstract 
Objectives: To assess whether body mass index (BMI) and body fat (BF) differ between RA 
patients, patients with non-inflammatory arthritis (Osteoarthritis – OA) and healthy 
individuals, and whether disease-specific measures of adiposity are required to  accurately 
reflect BF in these groups.  
Methods: A total of 641 individuals were assessed for BMI (kg/m2) and BF (bioelectrical 
impedance). Of them, 299 [174 RA, 43 OA and 82 healthy controls (HC)] formed the 
observation group and 342 (all RA) the validation group. RA disease characteristics were 
collected. 
Results: ANOVA revealed significant differences between disease groups for BMI (p<0.05) 
and BF (p<0.001). ANCOVA showed that age accounted for the differences in BMI (F1,294 = 
5.10, p<0.05); age (F1,293 = 22.43, p<0.001), gender (F1,293 = 380.90, p<0.001) and disease (F2, 
293 = 18.7, p<0.001) accounted for the differences in BF. For a given BF, patients with RA 
exhibited BMI levels reduced by 1.83kg/m2 (p<0.001) compared to HC; there were no 
significant differences between OA and HC.  A predictive model for BF was developed 
(R2=0.769, p<0.001) and validated using Limits of Agreement Analysis against measured BF 
in the validation group (95%LIMAG = 6.17; CV = 8.94).  
Conclusions: In individuals with RA, BMI cut-off points should be reduced by 2 kg/m2 (i.e. 
to 23 kg/m2 for overweight and 28 kg/m2 for obesity). The equation developed can be used to 
accurately predict body fat from BMI in RA patients.  These findings may be important in the 
context of the cardiovascular comorbidity of RA.  
 
Key Words: Rheumatoid arthritis, cardiovascular risk, body mass index, body composition, 
bioelectrical impedance. 
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Introduction 
Excess body fat (BF) is a prominent health hazard [1] significantly contributing to the 
development of cardiovascular disease (CVD).[2] About two-thirds of patients who have had 
a myocardial infarction (MI) exhibit increased body weight.[3] Obesity increases the risk of 
coronary heart disease (CHD) through a number of different pathophysiological pathways, 
including insulin resistance, type 2 diabetes, hypertension and dyslipidaemia.[4, 5] 
Assessments for overweight or obesity include the calculation of body mass index [6] 
(BMI - in kg/m2) or more accurate estimations of relative adiposity (BF percentage) through a 
number of techniques (e.g., skinfold thickness, hydrostatic weighing, and bioelectrical 
impedance).[7] BF estimations require sophisticated equipment and trained personnel, 
whereas BMI is easy to obtain and is widely used in the routine clinical setting.   
In the general population, BMI of <25, 25-30, and >30kg/m2 indicate healthy, 
overweight, and obese individuals and associate with low, medium, and high CVD risk, 
respectively.[8, 9] However, BMI is only a proxy of body fat, [6] and over recent years it’s 
validity has been questioned.[3, 7, 10-13] Overweight as defined by BMI of >25, has poor 
specificity in detecting excess body fat in healthy men and women of all ages [6] as well as in 
patients with coronary heart disease.[3] In specific sub-populations, such as Indian-Asian,[10] 
women,[12-14] and large size athletes,[7] new BMI cut-off points have been suggested, that 
optimally reflect  BF and may better predict CVD risk.  
The weakness of BMI is that it does not distinguish between lean-body mass and fat 
mass. Consequently people of similar stature and weight, but different muscle content, will 
have the same BMI but different BF levels.  This tends to be more evident in individuals with 
low BMI levels.[6]  Such limitations of the BMI may explain the better cardiovascular 
outcomes observed in overweight and mildly obese patients with established CHD as 
compared to their normal-weight counterparts, who may have proportionately more BF.[3] 
Therefore, although it is well established that CHD risk increases with advancing BMI levels, 
[9] global cut-off points may be misleading for several populations.  
Central obesity poses a great risk for cardiovascular disease.[15, 16] Regional fat 
distribution, as measured by waist-to-hip ratio, has been proposed as a more accurate 
predictor of CHD risk than BMI.[15, 16] Indeed, it has been suggested that obesity should be 
redefined based on waist-to-hip ratio instead of BMI, since waist-to-hip ratio is significantly 
associated with MI risk in most ethnic groups.[17] However, its predictive strength can be 
negatively affected by gender and overall body weight, [18] in a way that pear- shaped or 
obese individuals might have optimal waist-to-hip ratio but increased overall body weight. 
More research is necessary to identify the optimal definition of obesity as a predictor for CHD 
in the general population and specific sub-groups.[19] 
Patients with rheumatoid arthritis (RA) have an increased risk for CHD events.[20] 
RA is a chronic inflammatory disease which affects predominantly synovial joints, causing 
pain, swelling, stiffness and eventually irreversible damage and deformity, all of which may 
lead to significant reduction in physical activity.  RA associates with increased mortality 
particularly from CHD,[20] most probably due to accelerated atherogenesis secondary to the 
metabolic and vascular effects of systemic inflammation.[21] Nearly two thirds of all 
individuals with RA experience involuntary loss of fat-free mass and progressively increased 
fat mass in the presence of stable or even slightly decreased weight, a condition referred to as 
rheumatoid cachexia.[22] The exact mechanisms causing rheumatoid cachexia remain 
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undetermined, but muscle loss due to systemic inflammation and reduced physical activity 
may both contribute.[23] 
We hypothesised that for a given BMI, RA patients exhibit significantly higher 
proportions of fat mass than healthy individuals, or even than patients with movement 
restriction due to a non-inflammatory arthritis, such as osteoarthritis (OA).  The possible 
consequences of this, in the context of the increased CVD mortality in RA, are obvious. In the 
present study we aimed to investigate whether BMI and BF differ according to arthritic 
disease (OA vs RA) and within RA according to disease state (e.g. active vs inactive, early vs 
established disease). We also developed and validated RA-specific BMI cut-off levels and 
algorithms to calculate BF from BMI.   
 
Methods 
Participants 
Consecutive patients attending routine rheumatology or orthopaedic outpatient clinics 
at the Dudley Group of Hospitals NHS Trust, UK, and healthy controls (Hospital and 
University staff) were invited to participate. The study had Local Research Ethics Committee 
approval by the Dudley Ethics Committee, and all volunteers provided informed consent.  
The observation group (n=299) included 174 volunteers with RA (1987 revised ACR criteria 
[24]), 43 with OA of the hip [25] or knee,[26] and 82 healthy controls (individuals who by 
self-report did not have any known clinical conditions and were taking no medication). The 
validation group (n=342) consisted of RA patients only. Demographic and disease 
characteristics from all subjects appear in Table 1. 
 
Assessments 
All volunteers were subjected to the same data collection procedures overseen by the 
same trained investigators. Specifically, standing height was measured to the nearest 0.5cm 
on a Seca 214 Road Rod portable stadiometer. Body composition was assessed by 
Bioelectrical Impedance, using a Tanita BC-418 MA Segmental Body Composition Analyzer, 
which incorporates 8 tactile electrodes (Tanita Corporation, Tokyo, Japan). This apparatus, 
measures total body mass and assesses body composition in terms of percentage body fat, fat 
mass, fat free mass and total body water, as well as fat distribution in different body segments 
(abdominal and peripheral fat) and has a standard error of <3.[27] After initial manual entry 
of their demographic details, participants stood bear-footed on the analyzer and held the 
handgrips provided until the apparatus printed the results. BMI (kg/m2) was calculated on the 
basis of measured height and weight.  In RA patients, contemporary serological inflammation 
and clinical disease activity were assessed by the erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP) [using routine laboratory procedures] and the Disease Activity Score-
28 (DAS28).[28] Disease duration was recorded from review of the patients’ hospital notes. 
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Table 1: Demographic and disease characteristics of all volunteers [mean (sd)]  
 Observation group Validation Group 
 MALE (n= 110) FEMALE (n= 189) Male Female 
 RA OA HC RA OA HC RA RA 
N 56 15 39 118 28 43 99 243 
Age 60.6 (11.8)** 56.7 (13.3)* 45.1 (13.3) 59.6 (12.2)** † 52.8 (12.5)* 46.8 (11.5) 62.1 (11.6) 61.7 (11.9) 
Height 173.6 (7)* 171.3 (6.7)* 177.3 (6.7) 159.1 (6.5)** 161 (5) 163.6 (6.9) 174 (6.8) 160,4 (6.7) 
Weight 83.6 (13.3) 78.4 (14.8) 80.9 (11.4) 68.6 (15) 70.8 (16.5) 68.1 (16.3) 82.7 (15.8) 70.2 (14.4) 
BMI 27.7 (4.3)* 26.8 (4.7) 25.7 (3) 26.9 (5.7) 27.2 (5.7) 25.4 (5.5) 27.3 (4.4) 27.3 (5.3) 
BF 28.7 (7.7)** 24.8 (7.9)* 19.2 (5.2) 38.3 (7.3)** † 35.2 (8.5) 32.1 (8.2) 27 (6.4) 38.3 (7.1) 
Trunkal Fat 30.5 (8)** 26.6 (8.9)* 21.4 (6) 35.7 (8.6)** † 31.6 (9.6) 29.1 (8.7) 27.4 (7.7) § 35.4 (8.1) 
DAS28 4.2 (1.2)   4.3 (1.4)   4.1 (1.4) 4.3 (1.4) 
ESR 23.2 (18.5)   26 (22.1)   25.3 (21.5) 30 (26.3) 
CRP 15.6 (15)   15.8 (14.9)   16.8 (18.6) 17.6 (23.6) 
Disease Duration 11.4 (10.2)   11.3 (9.9)   12.5 (11) 13.2 (11) 
One-way ANOVA:  * Significant difference compared to HC (p<0.05) 
** Significant difference compared to HC (p<0.001) 
† Significant difference compared to OA (p<0.05) 
§ Significant difference compared to experimental RA group (p<0.001) 
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Data management and analysis 
Data were inserted in a purpose-designed spreadsheet (Microsoft Excel 2003) and 
audited for accuracy weekly. They were exported for analysis to The Statistical Package for 
Social Sciences version 11.0 (SPSS Inc. Chicago, IL, USA). Preliminary evaluation of the 
variables using a Kolmogorov-Smirnov test of normality revealed that none of them required 
logarithmic transformation to reach normality. Means (sd) were calculated for all variables. 
The method of analysis was to define either BMI or BF as the dependent variable and 
then to incorporate all other known parameters thought to influence these measures of 
adiposity as either factors, in an ANOVA, or factors with covariates in an ANCOVA. Factors 
included gender and disease status (RA, OA and HC) while age, disease activity and duration, 
and serological inflammation were entered as continuous covariates. The initial ANCOVA 
analysis incorporated all these factors and covariates, but only those found to be significant 
were subsequently retained and reported in the prediction equation model below.  
Within the RA population of the observation group, correlations of disease activity 
(DAS28, ESR, CRP) and disease duration with BMI and BF were obtained for each gender. 
RA patients were also sub-grouped according to their clinical disease activity (DAS remission 
< 2.6, mild 2.7 – 3.2, moderate 3.3 – 5.1, high > 5.1 [28]), serological inflammation (ESR [29] 
and CRP [30]), disease duration (early <3 years, established 3-10 years, longstanding >10 
years), rheumatoid factor positivity (ever), or corticosteroid administration (yes/no ever): 
differences between these sub-groups in relation to BMI and BF were assessed using 
ANCOVA (Table 2). The level of significance was set at p<0.05.  
The external validity of the predictive model was tested with the Limits of Agreement 
(LIMAG) method [31] against BF of the validation group. The Limits of Agreement were 
obtained as follows: 
i) We calculated the mean (d) and the standard deviation (s) of the differences that 
indicate the level of bias and the random variation between the two measures of BF 
(i.e. the predicted BF and measured BF of the validation group, respectively). 
ii) Provided the differences are normally distributed, the 95% ‘Limits of Agreement’ are 
given by: d ± (1.96×s). 
Bland and Altman [31] argue that, provided that differences within these limits are not 
clinically important, the two measurement methods can be used interchangeably.  
 
Results 
Observation group: 
Within the RA population of the observation group, no significant correlations were found 
between DAS28, ESR, CRP, disease duration and BMI or BF. Similarly, when RA patients 
were grouped according to these variables as well as rheumatoid factor positivity and 
corticosteroid use, no significant differences for BMI and BF were observed (p>0.05 in all 
cases, see Table 2). 
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Table 2: BMI and BF of RA patients (observation group) according to categorisation based 
on their disease characteristics. 
Disease 
Characteristics 
Categories BMI BF 
  Male Female Male Female 
Remission (<2.6)  27.2 (3.46) 27.2 (5.6) 26.5 (7.6) 39.5 (6.7) 
Mild (2.7- 3.2) 28 (4.3) 27.3 (4.6) 28 (6) 39.3 (6.6) 
Moderate (3.3 -5.1) 27.8 (4.5) 27 (5.3) 27.4 (6.8) 37.3 (7.7) 
DAS28  
(DAS28 score) 
High (>5.1) 25.3 (5.5) 27.3 (5.5) 26.1 (5.6) 37.7 (7.2) 
Normal* 27.9 (4.4) 26.9 (4.8) 27.1 (7.2) 38.3 (6.3) ESR (mm/ h) 
High 26.4 (4.6) 27.6 (6.1) 26.7 (5.9) 37.6 (8.9) 
CRP (mg/ L) Low (<3) 26.5 (2.4) 28.3 (6.2) 25.9 (5.4) 38.5 (8.7) 
 
Normal (3 – 8) 27.8 (4.7) 26.5 (4.7) 26.7 (8) 37.6 (6.6) 
 
High (>8) 26.9 (4.6) 27.6 (5.7) 27.3 (5.8) 38.3 (7.9) 
Early (<3) 26.4 (5) 26.1 (5) 26.4 (7.9) 37.9 (8.3) 
Established (3-10) 28.8 (4.1) 27.8 (5.7) 27.8 (6.3) 38.2 (7.5) 
Disease 
Duration 
(years) Longstanding (>10) 26.8 (4.4) 27.1 (5.1) 27.7 (5.7) 38.8 (6.7) 
Positive 26.6 (3.6) 27.2 (5.7) 25.1 (6.7) 38.3 (7.3) Rheumatoid 
Factor Negative 27.5 (5) 27.1 (5.1) 27.7 (6.4) 37.9 (7.3) 
Yes 27.1 (4.4) 27.3 (5.3) 26.2 (6) 38.1 (7.4) Corticosteroid 
Administration No 24.5 (4.9) 26.7 (5.3) 27.8 (7.3) 37.7 (7) 
For all differences between groups: p>0.05 
* Normal ESR: < 50 years: male <15, female <20 
> 50 years: male <20, female <30 
 
 
Between the different disease groups, one-way ANOVA revealed significant 
differences in BMI (p<0.05) and BF (p<0.001; Table 1): RA males had higher BMI and BF 
(including trunkal fat) than HC males, and RA females had higher BF than HC females, even 
though their BMI did not differ significantly. ANCOVA revealed that BMI differences 
between the groups were mainly due to the significant effect of the covariate age (F1,294 = 
5.10, p <0.05) and not due to disease (F2,294 = 1.00, p >0.05), gender (F1,294 = 0.59, p >0.05), 
or their interactions. 
ANCOVA also revealed that RA and OA patients exhibited lower BMI levels than 
their HC for a given BF. However, differences were only significant for the RA patients [RA:-
1.826 kg/m2 (p<0.001); OA: -0.352 kg/m2 (p>0.05)]. BMI was significantly (p<0.001) 
predicted by age, disease, gender and BF (R2= 0.58). 
When BF was adopted as the dependent variable, ANCOVA identified significant 
differences between disease groups (F2,293 = 18.70, p<0.001) and gender (F1,293 = 380.90, 
p<0.001) together with a significant covariate, age (F1,293 = 22.43, p<0.001). The contribution 
of BMI as a covariate in this analysis was also significant (F1,293 = 370.74, p<0.001). For a 
given BMI, RA patients exhibited significantly increased levels of BF (4.273, p<0.001) 
compared to healthy controls. The difference for OA patients was non-significant (1.648, 
p>0.05). The variation of BF was predicted by age, gender, BMI, and disease type (R2= 0.769, 
p<0.001). This was only very slightly improved (for RA) by the addition of RA disease 
duration (F1,293 = 0.340, p>0.05) in the equation (from 76.9% to 77.1%), so we did not include 
this variable in the final model. The predictive model obtained from this analysis is:  
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BF = Disease Status + Gender - 0.719 + 0.108 x Age + 1.059 x BMI 
Disease status Gender 
RA = 4.273 
OA = 1.648 
HC = 0 
Male = -11.294 
                   Female = 0 
 
Validation group: 
To establish external validity of our predictive model, we assessed its agreement with 
the measured BF in 342 patients with RA. Preliminary analyses for LIMAG revealed no 
heteroscedasticity, thus the LIMAG can be reported as absolute measurements.[31] Our 
analyses suggested that the bias of our prediction is 0.4 (i.e., our model over-predicts BF by 
0.4) with a standard error of 3.2 (95%LIMAG = 6.17, coefficient of variation = 8.9; Figure 1). 
The difference is statistically significant (t = 2.3, p < 0.05), but the coefficient variation (CV = 
8.9) is within acceptable limits. 
 
---Figure 1 about here--- 
 
RA-specific BMI cut-off levels: 
The fact that patients with RA exhibited increased BF values for a given BMI 
compared to HC, suggested that BMI cut-off points in the RA population would be more 
appropriate if they were reduced by approximately 2 kg/m2 (to 23 and 28 kg/m2 for 
overweight and obesity respectively). We therefore compared the proportions of subjects in 
each group that would be correctly classified as overweight or obese using the widely 
accepted BMI cut-offs of 25 and 30 kg/m2 vs. the proposed (for RA) 23 and 28 kg/m2 vs. the 
age- and gender specific cut-off points of measured BF. This analysis showed that 9% of male 
and 15% of female RA patients would be misclassified as of normal weight based on 
traditional BMI cut-offs. Such misclassification was not a problem either for OA or HC, 
where if anything, BMI overestimated BF. Application of the proposed RA-specific BMI cut-
offs of 23 and 28 kg/m2 corrected this misclassification (Figure 2a).  A modified, RA-specific 
BMI chart for the classification of patients with RA into underweight, normal, overweight and 
obese categories was developed and is provided in Figure 2b. 
 
---Figure 2 about here--- 
 
Discussion 
The validity of BMI as an acceptable measure of overweight or obesity, and as an 
accurate reflection of body fat (BF) content, has been repeatedly questioned and the need for 
population-specific BMI cut-off points has been highlighted.[7, 10-14]  Ideally, individualized 
assessment of BF should be pursued in the clinical setting, as BF percentage is a more reliable 
measure of fatness than BMI, at least in the general population.[32] Indeed, our data indicate 
that only 58% of the variance in BMI can be predicted, as opposed to 77% in BF.  BF in vivo 
can be determined via a number of methods such as underwater weighing, dual-energy x-ray 
absorptiometry, total body water, total body nitrogen, 40K whole body counting, and urinary 
creatinine excretion.[33-35] BF can also be estimated from the thickness of partial 
subcutaneous fat, near-infrared rays, and ultrasound.[36] However, none of these methods can 
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be practically used in the routine clinical setting as they require sophisticated apparatus and 
specialised personnel.[34] 
In recent years, a bioelectrical impedance method for the estimation of BF in different 
populations  has become popular and widely recommended, as it is reliable, objective, 
practical, relatively inexpensive, and does not require highly trained personnel.[33, 34] The 
validity of this method has been confirmed in various studies.[33, 37-40] Devices with eight 
tactile electrodes using single frequency electrical current, similar to the one used in this 
study, generate highly reproducible measurements of total BF and segmental fat distribution. 
[41] Their correlation with the “gold standards” of dual-energy x-ray absorptiometry and 
hydrostatic weighing is 0.90 and 0.80 respectively, with a standard error of around 3.0, 
producing a co-efficient of variation of <10%.[33] This suggests that bioelectrical impedance 
measurements (especially when using eight electrodes) are valid and suitable for body 
composition studies.[33, 40, 41] Patients are usually happy to undergo such a measurement 
due to its simplicity and similarity to normal weighing.   
In the absence of the necessary equipment or expertise, the predictive model presented 
here can be used to easily calculate BF of RA patients from BMI. The cross-validation of this 
predictive model in patients with RA is reassuring. Even though there was a statistically 
significant difference between the measured and the predicted BF, closer examination of the 
means indicates that this difference is at a level of less than 0.5% of BF with a co-efficient of 
variation of < 10%. The statistical significance of such a small difference can be attributed to 
the very large number of the validation group and is clinically not significant. However, the 
parts of the equation referring to OA patients and healthy individuals need further prospective 
validation in sufficiently large samples of the relevant populations. 
BMI remains the most commonly used indicator of body fatness in the clinical setting, 
and the cut-off points of 25 and 30kg/m2 (for overweight and obesity, respectively) used for 
the general population are also routinely applied in RA patients.  This study shows that 
application of these BMI cut-off points misclassified 9% of male and 15% of female RA 
patients in terms of actual body fatness. For a given BMI, RA patients exhibited an average 
4.3% increase in BF compared to healthy controls. In contrast, for the same level of BF, RA 
patients had BMI values almost 2 kg/m2 lower than those of healthy controls. We propose that 
BMI cut-off points in the RA population should be lowered to 23kg/m2 (from 25kg/m2) for 
overweight, and 28kg/m2 (from 30kg/m2) for obesity. The lowest limit for normal BMI (i.e. 
18.5kg/m2) should remain unaltered, as low BMI levels have been related to increased 
cardiovascular risk in patients with RA.[42, 43] We also provide a chart for the classification 
of RA patients in normal, overweight and obese categories according to these BMI cut-offs, 
for use in the routine clinical setting (Figure 2b). 
The most likely explanation for the BMI and BF differences observed in RA is 
rheumatoid cachexia associated with the chronic inflammatory response, given that such 
differences were not as prominent in OA. RA patients experience accelerated involuntary loss 
of fat-free mass, predominantly in the skeletal muscle, in excess of what is normally expected 
due to the aging process.[44]  Although the underlying mechanisms for rheumatoid cachexia 
remain unknown, possible contributing factors include the overproduction of inflammatory 
cytokines such as Tumour Necrosis Factor α and Interleukin-1 β.[44, 45] Our sub-analyses 
within the RA population revealed that neither BMI nor BF were associated with current 
clinical or serological disease activity, seropositivity for rheumatoid factor (which tends to 
associate with more severe disease) or corticosteroid administration. This is not totally 
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surprising as disease activity may vary within small periods of time, depending on medication 
and the disease itself, whereas changes in body composition are longer-term processes. On the 
other hand, disease duration appeared to be of some importance. It is possible that most 
alterations in body composition of RA patients occur in the first few years of the disease, as it 
has previously been reported,[22] irrespective of disease characteristics or medical treatment.  
The results of the present study are reminiscent of the observations made for Asian 
populations, which have significantly higher CVD risk than Caucasians: BF in Asians has 
been found to be 3-5% higher than that of Caucasians with similar BMI, whereas BMI was 3-
4 kg/m2 lower than that of Caucasians with similar BF.[33] Differences in body build (trunk-
to-leg-length ratio and slenderness) and in muscularity have been suggested as possible 
explanations for these discrepancies. As a result, new cut-off points for Asian populations 
have been set at 23 kg/m2 and 27 kg/m2 for overweight and obesity, respectively,[10] and 
have been shown to be more sensitive in identifying Asians at increased risk for CVD.[46]  
In our participants, lowered BMI cut-off points would reflect an average reduction of 
5-6 kg, or 8%, in the ideal weight (the weight one should have in order to be below the BMI 
cut-off for overweight). Such reductions in body weight are likely to lead to physiological 
benefits in the cardiovascular system: in the general population, even a 5% reduction of body 
weight is known to affect favourably most classical CVD risk factors.[47, 48] 
The reduced BMI cut-off points for RA suggested here may be of significance both for 
the management of individual patients and for further research into the cardiovascular 
morbidity and mortality of RA.  In the clinical arena, the reduction of these thresholds would 
identify an additional 10-15% of people with RA as overweight or obese, and may trigger 
closer scrutiny for other CVD risk factors and appropriate intervention, if necessary. 
Moreover, obesity, defined by the BMI, is one of the WHO criteria for the metabolic 
syndrome [47].  Aggressive identification and reduction of classical CVD risk factors in 
patients with RA is an obvious strategy for reducing the increased cardiovascular mortality of 
this disease.[20]  From the research perspective, the new thresholds may trigger re-analysis of 
previously published cohorts or further analysis of prospective cohorts as to the importance of 
body fat as a predictor of CVD in RA and its association with other individual risk factors. 
We conclude that, in the clinical setting, body fatness of RA patients should be 
evaluated based on the BMI cut-off points of 23kg/m2 for overweight and 28kg/m2 for 
obesity.  In the absence of specialised equipment, if necessary, BF of patients with RA can be 
estimated from BMI using the equation provided. 
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Figure Legends 
 
Figure 1: Agreement between Predicted and Measured Fat in patients with RA.  Body 
fat was measured by bioelectrical impedance using a Tanita BC-418 MA Segmental Body 
Composition Analyzer. Predicted fat was assessed using the formula: BF = 4.273 + Gender - 
0.719 + 0.108 x Age + 1.059 x BMI. 95% Limits of Agreement were 6.17 with a coefficient 
of variation of 8.9. 
 
Figure 2a: Classification of male (top graph) and female (bottom graph) participants 
into obese, overweight, normal and underweight groups according to currently accepted 
BMI cut-off points (BMI), body fat content (BF) and RA-specific BMI cut-off points 
(RA-BMI).  Accepting BF as the most accurate assessment of body fatness, currently 
accepted BMI cut-off points misclassify a significant proportion of both males and females 
with RA (notice the difference in the respective bars).  This misclassification is corrected 
when the proposed RA-specific BMI cut-off points are applied. 
RA: patients with rheumatoid arthritis 
OA: patients with osteoarthritis  
HC: healthy controls 
BMI: classification according to existing body mass index (BMI) cut-off points of 25kg/m2 
for overweight and 30kg/m2 for obesity 
BF: classification according to age and gender specific cut-off points for body fat percentage 
RA-BMI: classification according to the proposed RA-specific BMI cut-off points of 23kg/m2 
for overweight and 28kg/m2 for obesity 
 
Figure 2b: BMI chart developed specifically for patients with RA.  
Values were calculated using the formula: BMI = weight (in kg) / height2 (in m) for the 
rheumatoid arthritis-specific BMI levels identified in the present study [23kg/m2 for 
overweight, 28kg/m2 for obesity].  The generally accepted lower threshold for normal BMI 
[18.5 kg/m2] was not altered. 
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